Table 1.
Demographics and Clinical Characteristics
| Variable* | All Patients | Patients With NAS ≥4 | Patients With F ≥2 | |
|---|---|---|---|---|
| N = 304 | n = 129 | n = 186 | ||
| Age, years | 52 (39, 59) | 52 (38, 59) | 54 (39, 60) | |
| Male sex, n | 156 (51.3) | 62 (48.1) | 97 (52.2) | |
| Current smoker, n† | 39 (12.8) | 21 (16.3) | 30 (16.1) | |
| History of smoking, n† | 57 (18.8) | 24 (18.6) | 37 (19.9) | |
| ALT, U/L | 72 (48, 109) | 87 (57, 122) | 80 (52, 120) | |
| AST, U/L | 52 (38, 75) | 63 (47, 87) | 62 (42, 85) | |
| CVD | Total, n | 30 (9.9) | 11 (8.5) | 20 (10.8) |
| Coronary heart disease, n | 16 (5.3) | 6 (4.7) | 11 (5.9) | |
| History of stroke, n | 14 (4.6) | 5 (3.9) | 9 (4.8) | |
| CVD in family history | 40 (13.2) | 17 (13.2) | 24 (12.9) | |
| Diabetes type 2, n | 110 (36.2) | 59 (45.7) | 87 (46.8) | |
| Arterial hypertension, n | 185 (60.9) | 82 (63.6) | 129 (69.4) | |
| Cholesterol,‡ mg/dL | 209 (183, 239) | 205 (172, 236) | 205 (177, 236) | |
| Triglycerides,§ mg/dL | 154 (115, 215) | 168 (119, 230) | 164 (120, 214) | |
| HDL‐C, mg/dL | 45 (38, 52) | 45 (38, 52) | 44 (36, 52) | |
| LDL‐C, mg/dL | Total | 131 (103, 152) | 126 (99, 149) | 128 (99, 148) |
| Lipid‐lowering drugs | Total, n | 49 (16.1) | 24 (18.6) | 37 (19.9) |
| Statins, n | 43 (14.1) | |||
| Other, n | 6 (2.0) | |||
| NASH | 151 (49.7) | 113 (87.6) | 124 (66.7) | |
| Cirrhosis | 40 (13.2) | 18 (14.0) | 40 (21.5) | |
| NAS | Median | 3 (2, 4) | 4 (3, 5) | |
| ≥4, n | 129 (42.4) | 129 (100) | 109 (58.6) | |
| Fibrosis ≥2 | 186 (61.2) | 109 (84.5) | 186 (100) | |
*
Data are expressed as medians and IQRs or as frequencies and percentages.
†
Data were available in 234 patients.
‡
Data were available in 289 patients.
§
Data were available in 288 patients.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase.